To earn $10,000 annually from Bristol Myers Squibb dividends, an investor needs about $250,000 at the current 3.94% yield, equating to nearly 4,000 shares. However, the company faces significant risks from patent expirations, especially on its top drug Eliquis, which could reduce revenue sharply by 2027-2028. Despite this, Bristol Myers Squibb has strong cash reserves and a growing portfolio of new drugs that may offset losses. Investors should monitor dividend coverage and pipeline developments closely to assess future payout stability.
Bristol-Myers Squibb (BMS) will release its Q3 earnings on October 27, following a Q2 revenue increase of 12.9% to $12.97 billion driven by strong sales of Camzyos and its oncology portfolio. Recently, BMS announced positive Phase 3 trial results for...
Moderna's stock surged 7% as investors anticipate the release of late-stage melanoma vaccine data at the European Society for Medical Oncology congress in Madrid on October 24. The data involves a combination of Moderna's intismeran autogene and Merc...
